1. Introduction
===============

According to a FAO report, the average consumption of aquaculture products relative to total *per capita* fish for human consumption rose from 14% in 1986 to 47% in 2006 and it can be expected to reach 50% in the next few years. However, the development of aquaculture farming will have to be backed up with appropriately relevant management practices, in particular by decreasing its environmental impact and limiting the associated infectious epizooties. Indeed, as in all animal industries, development and intensification generate higher population densities which exacerbate disease processes, leading to stock mortality \[[@b1-marinedrugs-08-01153]\]. Major economic losses in cultured fish worldwide result from a relatively small number of opportunistic pathogens bacteria \[[@b2-marinedrugs-08-01153]\]. *Vibrio* is one of the most important pathogenic recognized in larval cultures, provoking a high mortality \[[@b3-marinedrugs-08-01153],[@b4-marinedrugs-08-01153]\]. Furthermore, fear of aquaculture farming increases with climate change. Indeed, a recent report has shown that numerous bacteria display greater virulence at higher temperatures due to reduced resistance and increased virulence and transmission \[[@b5-marinedrugs-08-01153]\]. At the same time, use of prophylactic antibiotics is detrimental to aquatic and terrestrial environments, animal and human health \[[@b6-marinedrugs-08-01153],[@b7-marinedrugs-08-01153]\]. That's why authorities such as the European Authority have chosen to limit antibiotic use as a curative situation. In this context, scientific communities have proposed friendly alternatives such as vaccines \[[@b1-marinedrugs-08-01153]\], antibiotic substitutes \[[@b8-marinedrugs-08-01153]\] or use of probiotic \[[@b9-marinedrugs-08-01153]\]. Bacteriocinogenic bacterial strains appear to be an excellent candidate for a friendly alternative since bacteriocin would be used as an antibiotic substitute \[[@b10-marinedrugs-08-01153]\], whereas bacteria would be a potential probiotic \[[@b11-marinedrugs-08-01153]\].

Bacteriocins are ribosomally synthesized proteinaceous compounds, lethal to bacteria closely related to the producing bacteria \[[@b10-marinedrugs-08-01153],[@b12-marinedrugs-08-01153]\], the latter being protected by an immunity phenomenon. The role of bacteriocins in microbial communities hasn't been well-established yet. Bacteriocins may serve as anti-competitor compounds enabling an invasion of a strain or species in an established microbial community \[[@b13-marinedrugs-08-01153]--[@b15-marinedrugs-08-01153]\] or act as communication molecules in bacterial consortia like biofilms \[[@b11-marinedrugs-08-01153]\]. Nevertheless, using pure bacteriocins is not practical since it has no economic basis. One way to substitute antibiotics smartly and sustainably will be the selection of bacteriocinogenic and anti-pathogenic strains from animal-associated bacterial microorganisms for use as probiotics.

In this review, the first section deals with a definition of probiotics and their mode of action, while the second part is dedicated to bacteriocin knowledge to date. Then an inventory of marine bacteriocin-like inhibitory substances (BLIS) producing bacteria in the literature is drawn up. The last section is about an efficient strategy to select bacteriocinogenic bacteria.

2. Probiotics for Aquaculture
=============================

In 1908 Elie Metchnikoff started the discipline of probiotics by reporting for the first time dietary supplements containing potentially beneficial micro-organisms. However, Kollath was the first to suggest, in 1953, the term "probiotics" to designate organic or inorganic substances that are essential to a healthy development of life \[[@b16-marinedrugs-08-01153]\]. Two decades later, Parker used the term "probiotic" to describe animal feed supplements that contribute to the gut microbial communities of the host \[[@b17-marinedrugs-08-01153]\]. In 1989, Fuller suggested another definition widely used since: "*A live microbial feed supplement which beneficially affects the host animal by improving its intestinal balance*" \[[@b18-marinedrugs-08-01153]\]. This revised definition differs from Parker's one by emphasizing the importance of live cells that permit the formal exclusion of antibiotics from the probiotics group. In 1999, Salminen proposed a new definition: "*Probiotics are microbial cell preparations or components of microbial cells that have a beneficial effect on the health and well-being of the host*" \[[@b19-marinedrugs-08-01153]\]. This implies that non-viable forms of probiotics have also been shown to have health effects and should not restrict the utilization of probiotics in food \[[@b20-marinedrugs-08-01153]\]. The International Scientific Association for Probiotics and Prebiotics recently adopted the definition of the World Health Organization: "*Probiotics are live microorganisms which when administrated in adequate amounts confer a health benefit on host*" \[[@b21-marinedrugs-08-01153]\].

Nevertheless, none of these definitions fit with aquaculture since aquatic animals have a much closer relationship with their environment than terrestrial ones. In fact, in seawater, pathogens proliferate independently of the host, so opportunistic organisms can reach a high density around aquatic animals \[[@b22-marinedrugs-08-01153]\]. Furthermore, it is admitted that bacteria present in aquatic environments influence the composition of the gut microbiota, with surrounding bacteria being continuously ingested \[[@b23-marinedrugs-08-01153],[@b24-marinedrugs-08-01153]\]. The intensive interaction between the environment and the farmed aquatic animals implies that the definition of probiotics has to be adapted for aquaculture. Based on this statement, a new definition for probiotics has been proposed: "*A live microbial adjunct which has a beneficial effect on host by modifying the host-associated or ambient microbial community, by ensuring improved use of the feed or enhancing its nutritional value, by enhancing the host response towards disease, or by improving the quality of its ambient environment*" \[[@b25-marinedrugs-08-01153]\].

This confers to aquaculture probiotics a large possibility to affect the host health positively \[[@b26-marinedrugs-08-01153]\] by competitive exclusion \[[@b27-marinedrugs-08-01153]\], by enzymatic contribution to digestion \[[@b11-marinedrugs-08-01153],[@b28-marinedrugs-08-01153],[@b29-marinedrugs-08-01153]\] and by enhancement of the immune response \[[@b30-marinedrugs-08-01153],[@b31-marinedrugs-08-01153]\] or by the production of inhibitory substances \[[@b9-marinedrugs-08-01153]\]. Inhibitory substance production is probably one of the most studied modes of probiotic action.

3. Bacteriocins
===============

3.1. Bacteriocin story
----------------------

To go back to the first bacteriocin descriptions amounts to studying the first works concerning bacterial antagonism. Such bacterial antagonism was described by the pioneers of microbiology during the last decades of the 19^th^ century. At that time, the molecular basis of bacterial inhibition was abstruse, so it was difficult to distinguish antagonism due to bacteriocins from that provoked by other compounds such as antibiotics, organic acids or hydrogen peroxide, except on the basis of their spectrum of activity, usually narrower than that of the other ones. Although Cornil and Babès suggested a very narrow antagonism within the genus *Staphyloccoccus* ("le staphylocoque empêche surtout le staphylocoque") in their 1885 treatise of bacteriology \[[@b32-marinedrugs-08-01153]\], the scientific community acknowledges the Gratia *et al.* findings \[[@b33-marinedrugs-08-01153]\] in 1925 as the first documented bacteriocin activity. Indeed, it was named colicin V by the same team in 1949 \[[@b34-marinedrugs-08-01153]\]and later microcin V \[[@b35-marinedrugs-08-01153]\].

The term bacteriocin did not appear until the fifties \[[@b34-marinedrugs-08-01153]\]. This bacteriocin definition is based on the properties of the colicins, that is to say, a lethal biosynthesis, a very narrow spectrum of activity limited to the same species as the producer bacteria and a receptor-mediated mechanism of action \[[@b36-marinedrugs-08-01153]\]. In those days, during the fifties and sixties, the bacteriocin world was mainly made up of bacteriocins from Gram negative bacteria \[[@b37-marinedrugs-08-01153],[@b38-marinedrugs-08-01153]\]. Three genera of Gram positive bacteria were studied for bacteriocin production: *Bacillus* sp., *Listeria* sp. and *Staphylococcus* sp., but it should be noted that during the first half of the 20th century, two lantibiotics, one of the most famous bacteriocins to date, were described. Indeed, the first observations of nisin activity could be those of Roger *et al.* \[[@b39-marinedrugs-08-01153]\], while subtilin was identified in 1944 from *Bacillus subtilis* \[[@b40-marinedrugs-08-01153]\]. The exotic amino acid sequences of nisin and subtilin were only elucidated in the early seventies \[[@b41-marinedrugs-08-01153],[@b42-marinedrugs-08-01153]\].

The eighties saw an increase in the number of publications on bacteriocin for both colicin type- and non colicin bacteriocins ([Figure 1](#f1-marinedrugs-08-01153){ref-type="fig"}). But the attribution of nisin GRAS-status by FDA in 1988 \[[@b43-marinedrugs-08-01153]\] would unleash interest in the bacteriocins produced by lactic acid bacteria. Indeed, the industrial applications and the medical and veterinary potential of these microorganisms considered as technological ones are enormous \[[@b44-marinedrugs-08-01153]--[@b48-marinedrugs-08-01153]\]. These bacteriocins have aroused a keen interest which has resulted in an exponential increase in the number of publications, while scientific publications about colicins, which may represent the most extensively studied bacteriocins to date, seem to be stabilizing ([Figure 1](#f1-marinedrugs-08-01153){ref-type="fig"}).

Such interest in LAB bacteriocins has resulted in applications as food preservatives, *eg* antimicrobial ingredients \[[@b45-marinedrugs-08-01153]--[@b50-marinedrugs-08-01153]\]. Over the last 20 years, 706 patents based on LAB bacteriocins activity have been recorded around the World, 421 of which were linked to food preservation, and 124 to animal probiotics (<http://www.freepatentsonline.com>). The non LAB bacteriocins are not devoid of application fields. Applications have also been suggested for plant protection \[[@b12-marinedrugs-08-01153],[@b51-marinedrugs-08-01153],[@b52-marinedrugs-08-01153]\], to prevent local infections in humans \[[@b53-marinedrugs-08-01153]\] and recently in aquaculture \[[@b11-marinedrugs-08-01153]\]. Two dedicated freely available bacteriocin online databases have been assembled: BACTIBASE \[[@b54-marinedrugs-08-01153]\] and BAGEL \[[@b55-marinedrugs-08-01153]\]. Moreover, bacteriocins are part of antimicrobial peptides and on this account, are referenced in various antimicrobial peptide databases such as APD2 \[[@b56-marinedrugs-08-01153],[@b57-marinedrugs-08-01153]\] or CyBase \[[@b58-marinedrugs-08-01153]\].

A new category of bacteriocins has emerged over the last two decades: that of the microcins ([Figure 1](#f1-marinedrugs-08-01153){ref-type="fig"}). These may be considered as the "little sisters" of colicins since they exhibit low molecular weight and are produced by enterobacteriae (for reviews see \[[@b35-marinedrugs-08-01153],[@b59-marinedrugs-08-01153],[@b60-marinedrugs-08-01153]\]). Besides, most microcins exhibit intensive post translational modifications yielding exotic amino acids \[[@b61-marinedrugs-08-01153]\]. In a way, microcins are counterparts of lantibiotics in Gram negative bacteria \[[@b61-marinedrugs-08-01153]\].

Only a few publications are dedicated to bacteriocin production by marine bacteria. Only a few BLIS have been described from marine bacteria and a unique bacteriocin has been fully characterized (see below). In light of marine bacterial biodiversity and the urgent requirement for antibiotic alternatives, we can assume that the marine bacteriocin category will grow exponentially in the near future.

3.2. Bacteriocin classification
-------------------------------

To date, about two hundred bacteriocins have been characterized (BACTIBASE, BAGEL). Bacteriocin classification is not well-established yet and is still the subject of debate. Although dating back to 1993, the bacteriocin classification defined by Klaenhammer is still the most cited one \[[@b62-marinedrugs-08-01153]\]. An update was proposed by Cotter *et al.* in 2005 \[[@b63-marinedrugs-08-01153]\] and debated by Heng and Tagg in 2006 \[[@b64-marinedrugs-08-01153],[@b65-marinedrugs-08-01153]\]. Bacteriocins are usually classified combining various criteria. The main ones being the producer bacterial family, their molecular weight and finally their amino acid sequence homologies and/or gene cluster organization. An overview of bacteriocins known to date, proposed in [Table 1](#t1-marinedrugs-08-01153){ref-type="table"}, shows two main categories: the protein-bacteriocins mainly produced by *Gracilicutes*, mostly enterobacteriae and the peptide-bacteriocins from *Firmicutes*, chiefly from LAB. Even so, this statement needs to be qualified since enterobacteriae and LAB were the main bacteria studied for bacteriocin production. Our feeling is that peptide bacteriocins from *Gracilicutes* such as microcins are no exceptions.

Colicins are protein-bacteriocins containing about 500--600 amino acid residues \[[@b66-marinedrugs-08-01153]\]. They are organized in three specific domains. Binding to a specific receptor of the target cell, which is the first step of colicin cytotoxic action is governed by the central domain of colicins. The *N*-terminal and *C*-terminal domains are respectively responsible for colicin translocation and antibacterial activity (for a review see \[[@b67-marinedrugs-08-01153]\]). They have been classified in two sub-classes, based on cross resistance \[[@b68-marinedrugs-08-01153]\], translocation system, mechanism of release from the producing cell, and size of encoding plasmids \[[@b69-marinedrugs-08-01153]\]. Group A, translocated by the Tol system and encoded by small plasmids, is composed of colicins A, E1 to E9, K, L, N, S4, U, and Y while group B, translocated by the TonB system and encoded by large plasmids, are made up of colicins B, D, H, Ia, Ib, M, 5, and 10.

Both groups act on sensitive cells by targeting either the inner membrane by pore formation or an intracellular target using enzymatic activity such as DNAse or RNAse \[[@b67-marinedrugs-08-01153]\]. Bacteriocins of such molecular weight are exceptions in *Firmicutes* compared with the colicin family. Only two have been described in LAB \[[@b79-marinedrugs-08-01153],[@b80-marinedrugs-08-01153]\]. Such protein-bacteriocins produced by LAB have been named class III bacteriocins. The others are specific of *Bacillus megaterium* \[[@b93-marinedrugs-08-01153]\], *Enterococcus faecalis* \[[@b81-marinedrugs-08-01153]\] or *Staphylococcus aureus* \[[@b82-marinedrugs-08-01153]\].

The peptide-bacteriocin group is produced by *Gracilicutes* and *Firmicutes* as well. Until 2007, the microcin group was composed of two classes, based on their post-translational modifications \[[@b94-marinedrugs-08-01153]\]. According to their gene cluster organization, this classification has recently evolved \[[@b35-marinedrugs-08-01153],[@b59-marinedrugs-08-01153]\] to give birth to two main classes and two sub-classes. Class I comprises the smallest microcins with molecular masses ranging from 1.1 kDa to 3 kDa ([Table 1](#t1-marinedrugs-08-01153){ref-type="table"}). They display drastic post-translational modifications leading to exotic structures such as thiazole and oxazole rings in MccB17 ([Figure 2](#f2-marinedrugs-08-01153){ref-type="fig"}). This class acts on sensitive cells by interaction with an intracellular target such as DNA gyrase inhibited by MccB17 \[[@b95-marinedrugs-08-01153]\]. The second microcin class is divided into two sub-classes. The microcin class IIa bridges the gap between colicin and microcin since these peptides are bigger (about 8 kDa) than a typical microcin and exhibit no modifications with the exception of a single disulfide bond formation. One of them, Microcin V (MccV) was previously called colicin V \[[@b35-marinedrugs-08-01153]\], the first documented bacteriocin \[[@b33-marinedrugs-08-01153]\]. Nevertheless, its gene cluster organization connects them undoubtedly to the microcin family \[[@b35-marinedrugs-08-01153]\]. Unlike previous microcins, class IIb microcins are chromosomally encoded, lacking disulfide bond, exposing a conserved serine-rich C-terminal and carrying for some of them a siderophore-type part (MccE492). MccE492 carries out its antibacterial activity by membrane permeabilization. But it was shown to target inner membrane proteins belonging to the mannose permease family \[[@b96-marinedrugs-08-01153]\].

The other main peptide bacteriocins family is the LAB one. Indeed, of the two hundred or so bacteriocins described to date, almost 90% are from LAB. With the exception of Helveticin J \[[@b79-marinedrugs-08-01153]\] and Milletricin \[[@b80-marinedrugs-08-01153]\], which are members of class III bacteriocins, they all are of peptidic nature. They have been divided into two main classes: class I and class II, the latter in turn containing three sub-classes ([Table 1](#t1-marinedrugs-08-01153){ref-type="table"}).

Lantibiotics have been defined as class I. Lantibiotic peptides undergo drastic posttranslational modification leading to unusual amino acid residues such as lanthionine. In a way, they are the counterpart of microcins in *Firmicutes*. To date, about 50 different lantibiotics have been described in LAB and non LAB bacteria such as *Staphylococcus aureus* \[[@b97-marinedrugs-08-01153]\]. Overall, lantibiotics are divided on the basis of their topology, that is to say their lanthionine bridge arrangements. Type-A lantibiotics such as nisin ([Figure 2](#f2-marinedrugs-08-01153){ref-type="fig"}) are linear and cationic peptides, while type-B ones are globular \[[@b86-marinedrugs-08-01153],[@b98-marinedrugs-08-01153]\]. The former exerts its antibacterial activity by membrane permeabilization by pore formation in a torroid manner \[[@b98-marinedrugs-08-01153]\] after binding to lipid II, while the latter targets intracellular enzyme function \[[@b98-marinedrugs-08-01153]\]. Another emerging lantibiotic class is the two-component lantibiotics such as haloduracin \[[@b99-marinedrugs-08-01153]--[@b101-marinedrugs-08-01153]\].

Class II bacteriocins are lightly modified peptides. These peptides are 20 to 70 amino acid residue-long. Extensive studies have been carried out about their mechanism of action. It has appeared that they use a common global procedure targeting a membrane-embedded domain of an integrated membrane protein \[[@b91-marinedrugs-08-01153]\]. The conformational modifications resulting from membrane protein--bacteriocin interactions lead to membrane perturbations, permeabilization and finally bacterial cell death \[[@b102-marinedrugs-08-01153]\]. It was divided into four sub classes on the basis of their activity. Class IIa was also named pediocin-like or anti-*Listeria* bacteriocins since all of them displayed antibacterial activity against *Listeria* spp. \[[@b62-marinedrugs-08-01153]\]. These bacteriocins are peptides sharing a highly conserved *N*-terminal part harboring a consensus sequence: -Y-Y-G-N-G-V-X-C-x-x-x-x-C ([Figure 2](#f2-marinedrugs-08-01153){ref-type="fig"}) where C residues are involved in a disulfide bridge \[[@b48-marinedrugs-08-01153]\]. Their more variable C-terminal part has been used for their segregation in four sub-groups \[[@b63-marinedrugs-08-01153],[@b102-marinedrugs-08-01153]\]. They act on target cells by a pore-forming mechanism of action \[[@b48-marinedrugs-08-01153],[@b87-marinedrugs-08-01153],[@b102-marinedrugs-08-01153]\]. This class constitutes the bacteriocin success story of the last twenty years. Class IIb is an original antimicrobial peptide class because it is made up of two independent peptides, each being active but both being required for optimal activity \[[@b102-marinedrugs-08-01153]\]. Around twelve such two-component bacteriocins have been described in LAB. Each time, the most active mix was obtained with equivalent concentration of each peptide \[[@b88-marinedrugs-08-01153]\]. LAB bacteriocin group IIc are real cyclic peptides since their *N*- and *C*-termini are covalently connected (for review, the reader is referred to \[[@b63-marinedrugs-08-01153],[@b89-marinedrugs-08-01153]\]). Their mechanism of action when explored was permeabilization of the inner membrane of target cells leading to cell death. Finally, unmodified and non-pediocin-like peptides and single peptide active bacteriocins form class IId. To date, about 32 different class IId peptides have been described \[[@b102-marinedrugs-08-01153]\].

3.3. Bacteriocin specificity
----------------------------

Bacteriocins are unique antimicrobial peptides. Indeed, the producing strain has to protect itself from its own peptides, so bacteriocin-producing bacteria have to develop some sort of immunity strategy. In addition to a structural gene, post-translational gene and export machinery, the gene cluster organization of bacteriocin encodes as well for an immunity protein. The latter ensures bacteriocin protection in various ways, depending on the bacteriocin mechanism of action.

Immunity to pore forming colicins is mediated by a 11 to 18 kDa small membrane protein. A direct and specific interaction within the inner membrane between the immunity protein and the *C*-terminal part of colicin achieves cell protection. Transmembrane helices have been shown to be the main motifs recognized by immunity proteins. Colicins targeting intracellular enzymes such as nuclease are inactivated by direct binding of the immunity protein (about 10 kDa) to the active domain of colicin leading to a 71-kDa heterodimer.

Microcin immunity still remains opaque, while that towards lantibiotic has been recently reviewed \[[@b103-marinedrugs-08-01153],[@b104-marinedrugs-08-01153]\]. Lantibiotic immunity is conferred by lipoprotein intercepting lantibiotic at the cytoplasmic membrane and/or ABC transporter--type membrane protein complex. Immunity to class II bacteriocins produced by LAB has recently been cleared up \[[@b91-marinedrugs-08-01153]\]. It implies that components of the mannose phosphotransferase system are receptors for both bacteriocin and the imunity protein \[[@b105-marinedrugs-08-01153]\]. To define the role of bacteriocins in producing bacteria is still a challenge. Its production entails advantages in colonizing or defending ecological niches for producing bacteria.

4. Marine Animal-Associated Microorganisms as Bacteriocin Producers
===================================================================

Marine animal-associated micro-organisms have been recently studied. Various authors have shown that these bacteria belong to the genera *Vibrio*, *Pseudoalteromonas*, *Aeromonas*, *Alteromonas*, and to the *Cytophaga*- *Flavobacterium*- *Bacteroides* group \[[@b106-marinedrugs-08-01153],[@b107-marinedrugs-08-01153]\]. Currently, there are relatively few reports in the literature of antibacterial peptide or proteins produced by marine bacteria that have identified step sequence/structure. Wilson *et al.* \[[@b107-marinedrugs-08-01153]\] have isolated eight marine bacteria which produced antibacterial substances from a variety of different marine invertebrates (oysters, barnacles, sponges, tunicates, sea urchins, seaweeds). The loss of activity, after proteolytic digestion of their extracts, has suggested a proteinceous nature.

An increasing number of compounds with antibacterial activity have been found to be produced by a variety of organisms present in the marine surface environment. Potentially, there are many cases in which products previously attributed to higher organisms may be produced by their associated microorganisms such as patellamide \[[@b92-marinedrugs-08-01153]\]. Finally, numerous studies have evaluated antimicrobial marine isolates from sponge, coral, alga and mollusc associated bacteria \[[@b106-marinedrugs-08-01153]--[@b108-marinedrugs-08-01153]\]. Nevertheless, only a few studies have focused on marine bacterium isolation from marine animals and the search for their ability to produce bacteriocins ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}).

4.1. BLIS from *Vibrio* sp
--------------------------

*Vibrio* species are ubiquitous in the marine environment and are commonly isolated from fish and shellfish specimens \[[@b109-marinedrugs-08-01153]\]. Some species may be pathogenic to marine life, but some do not appear to affect them. Due to their capability to occupy this ecological niche they have been studied for their capacity to produce bacteriocin-like inhibitory substances (BLIS). Zai *et al.* \[[@b110-marinedrugs-08-01153]\] have isolated and identified fifty strains of the genus *Vibrio* isolated from the gills and gut region of healthy and infected catfishes (*Arianus thalassinus*). BLIS was detected and called Vibriocin AVP10 ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}).

Fresh and frozen seafood were studied by Carraturo *et al*. \[[@b111-marinedrugs-08-01153]\]. They have isolated three non-pathogenic (for humans) species of *Vibrio* (*V. mediterranei* 1, *V. mediterranei* 4 and *V. fluvialis*) displaying antagonistic activity on solid agar medium against pathogenic *V. parahaemolyticus* and *V. mediterranei*. A partial purification of a BLIS produced by *V. mediterranei* 1 was reported. Its proteinaceous nature was revealed by enzymatic degradation by proteinase K. Thanks to size exclusion chromatography, Carraturo *et al*. \[[@b111-marinedrugs-08-01153]\] have purified an antimicrobial fraction whose molecular mass was determined by SDS-PAGE to be 63--65 kDa corresponding to a mixture of unrelated polypeptides, including the bacteriocin.

Furthermore, *V. harveyi* is a serious pathogen of many vertebrate and invertebrate marine animals \[[@b112-marinedrugs-08-01153],[@b113-marinedrugs-08-01153]\]. McCall and Sizemore \[[@b114-marinedrugs-08-01153]\] have reported for the first time the production of a bacteriocin in a strain of *Beneckea harveyi* (*V. harveyi*). The bacteriocin, 'harveyicin SY', with an estimated molecular mass of 24 kDa, was lethal to two strains of *V. harveyi*, KN96 and BBP8 ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). Harveyicin SY was susceptible to proteolytic enzymes, and is apparently plasmid associated \[[@b114-marinedrugs-08-01153],[@b115-marinedrugs-08-01153]\].

Prasad *et al*. \[[@b112-marinedrugs-08-01153]\], whilst screening various *V. harveyi* isolates from their culture collection have recognized a possible BLIS production by a strain of *V. harveyi* (VIB 571). Interestingly, this strain has been demonstrated to be pathogenic to rainbow trout (*Oncorhynchus mykiss*) and Atlantic salmon (*Salmo salar*) \[[@b113-marinedrugs-08-01153]\].

Inter-strain and inter-species inhibition mediated by a bacteriocin-like inhibitory substance (BLIS) from *V. harveyi* VIB 571 was demonstrated against four isolates of the same species and *V. fischeri*, *V. gazogenes* and *V. parahaemolyticus* ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). The crude BLIS, which was obtained by ammonium-sulphate precipitation of the cell-free supernatant of a 72 h broth culture, was inactivated by lipase, proteinase K, pepsin, trypsin, pronase E and SDS. Incubation for 10 min at more than 60 °C resulted in loss of activity. On the other hand, antibacterial activity was not affected by pH. Anion-exchange chromatography, gel filtration, SDS-PAGE and two-dimensional gel electrophoresis revealed the presence of a single major peak, comprising a protein with a pI of \~5.4 and a molecular mass of \~32 kDa ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). The N-terminal sequencing of the \~32 kDa protein yielded: D-E-Y-I-S-X-N-K-XS-S-A-D-I where 'X' may be cystein or modified amino acid residues.

Other vibriocins were isolated by Shehane and Sizemore \[[@b116-marinedrugs-08-01153]\]. Their aim was to identify bacteriocins effective against *V. vulnificus* in seafood. Isolates from estuaries near Wilmington (NC, USA) containing plasmids were checked for antimicrobial activity which was not due to lytic bacteriophage or small, non specific molecules. Three bacteriocin producers of *V. vulnificus* were detected and their inhibitory spectra determined ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). Strain IW1 inhibited few strains of *V. vulnificus*; BC1 inhibited several strains of *V. vulnificus*, *V. cholerae* and *V. parahaemolyticus* and BC2 inhibited all tested *Vibrio* spp, *Plesiomonas shigelloides* and *E. coli*. Loss of inhibitory activity coincided with loss of the bacteriocinogenic plasmid. The molecular weights of the bacteriocins were estimated to be 9.0 kDa for IW1, 7.5 kDa for BC1 and 1.35 kDa for BC2 thanks to size exclusion chromatography. IW1 was heat labile, while BC1 was moderately stable except at extreme temperatures. BC2 was very stable and maintained its activity when frozen, autoclaved or exposed to extreme pH values \[[@b116-marinedrugs-08-01153]\]. The authors suggested that these bacteriocins might provide a tool for the removal of *V. vulnificus* from seafood.

Strain *Vibrio* sp. NM 10 was isolated from spotnape ponyfish (*Leiognathus nuchalis*) collected in coastal regions of Enoshima Island, Kanagawa, Japan. This strain exhibited high activity against *P. piscicida* K-III, but was also able to inhibit *E. coli* IAM 1264, *V. vulnificus* RIMD 2219009 and *Enterococcus seriolicida* YT-3 \[[@b117-marinedrugs-08-01153]\]. The antibacterial substance produced by *Vibrio* sp. NM 10 is a proteinaceous heat-labile substance with a molecular mass of less than 5 kDa. These facts strongly suggest that the antibacterial substance is either a bacteriocin or a bacteriocin-like substance \[[@b117-marinedrugs-08-01153]\].

4.2. BLIS from marine *Aeromonas* sp
------------------------------------

Authors Moro *et al*. \[[@b118-marinedrugs-08-01153]\] and Messi *et al*. \[[@b119-marinedrugs-08-01153]\] have shown their interest in evaluating BLIS production in *Aeromonas hydrophila*. All strains of *Aeromonas hydrophila* in these two studies demonstrated inhibitory activities against several strains of *Staphylococcus aureus* ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). Messi *et al*. \[[@b119-marinedrugs-08-01153]\] have demonstrated further inhibitory effect against *Listeria species, Streptococcus agalactiae* and *Lactobacillus* sp. No inhibition was observed against all Gram-negative strains assayed, including related species (*Aeromonas sobria* ATCC 43979, *A. caviae* ATCC 13137). Such an inhibitory spectrum is not compatible with the bacteriocin definition.

4.3. BLIS from marine *Pseudoalteromonas* sp
--------------------------------------------

Longeon *et al*. \[[@b121-marinedrugs-08-01153]\] investigated bacteria collected from different substrates on the littoral of Brittany and they focused their attention on a *Pseudoalteromonas* sp. named X-153 that exhibited high antimicrobial activity. Purification of the active protein P-153 from the bacterial cells was achieved. This antibacterial protein was evaluated by size exclusion chromatography to be of 280 kDa size. This antibacterial protein was shown to be active against both gracilicutes (ichthyopathogenic *Vibrio*) and firmicutes (*Staphylococcus epidermidis, Propionibacterium acnes* and *P. granulosum*) ([Table 2](#t2-marinedrugs-08-01153){ref-type="table"}). Such a broad spectrum of activity is not consistent with the definition of a bacteriocin.

4.4. Bacteriocin from Firmicutes and LAB associated to marine animals
---------------------------------------------------------------------

It is generally considered that Gram-positive bacteria, including lactic acid bacteria, are numerically dominant members of the normal microbiota in the gastrointestinal tract of endothermic animals at an early stage of their lives \[[@b122-marinedrugs-08-01153]\]. The gastrointestinal microbiota of healthy fish is usually composed of lactic acid bacteria belonging to the genera *Streptococcus, Lactobacillus, Carnobacterium, Leuconostoc* \[[@b122-marinedrugs-08-01153]\]. Divercins and piscicocins have been fully characterized from *Carnobacterium* isolated from fish intestine ([Table 3](#t3-marinedrugs-08-01153){ref-type="table"}). These two bacteriocins belong to class IIa of bacteriocins produced by LAB (see [Table 1](#t1-marinedrugs-08-01153){ref-type="table"}, for review the reader is referred to \[[@b123-marinedrugs-08-01153]\]).

In 2004, Pirzada *et al*. \[[@b120-marinedrugs-08-01153]\] isolated and studied a bacteriocinogenic strain ZM81, a Gram positive pleomorphic rod, which was isolated from the open sea region of Karachi. The proteinaceous nature of the cell-free supernatant of marine strain ZM81 was defined by enzyme degradation with pronase and trypsin. Fractionization of the crude bacteriocin thanks to a molecular weight cut-off membrane showed an enrichment of activity in the fraction containing \>10 kDa bacteriocin-like inhibitory substance. BLIS produced by Marine Bacterium ZM81 is heat labile and exhibits activity within a wide pH range of 4--12 \[[@b120-marinedrugs-08-01153]\].

4.5. Bacteriocin from marine cyanobacteria
------------------------------------------

While most small peptides found in *Cyanobacteria* are biosynthesized by nonribosomal peptide synthetases \[[@b131-marinedrugs-08-01153]\], a microcin-like pathway for the biosynthesis of a family of cyclic peptides, the patellamides ([Figure 2](#f2-marinedrugs-08-01153){ref-type="fig"}), has been recently reported in *Prochloron didemni*, a cyanobacterial symbiont of tropical ascidians \[[@b92-marinedrugs-08-01153]\]. The patellamides are moderately cytotoxic and composed of a pseudosymmetrical, cyclic dimer, with each substructure having the sequence thiazole-nonpolar amino acid-oxazoline-nonpolar amino acid. Despite these unusual features, patellamide biosynthesis is ribosomal \[[@b132-marinedrugs-08-01153]\]. The discovery of patellamides has provided first insight into the biosynthesis of microcin-like peptide distribution and versatility in *Cyanobacteria* \[[@b133-marinedrugs-08-01153]\].

The patellamide family are cyclic octapeptides ([Figure 2](#f2-marinedrugs-08-01153){ref-type="fig"}) characterized by the presence of thiazole and oxazole moieties. Although nonribosomal biosynthesis was anticipated for the formation of these peptides, heterologous expression of a microcin-like gene cluster discovered in the genome of the cyanobacterium *Prochloron didemni* unambiguously showed that these peptides are produced by a ribosomal pathway \[[@b92-marinedrugs-08-01153],[@b133-marinedrugs-08-01153],[@b134-marinedrugs-08-01153]\]. An increasing number of other cyclic peptides containing heterocyclic amino acids has recently been isolated from planktonic and other animal-associated *cyanobacteria*, including nostocyclamide \[[@b135-marinedrugs-08-01153]\], tenuecyclamides \[[@b136-marinedrugs-08-01153]\], venturamides \[[@b137-marinedrugs-08-01153]\], dendroamides \[[@b138-marinedrugs-08-01153]\], and microcyclamides \[[@b139-marinedrugs-08-01153]\]. The variety of structures is reflected in an equally large variety of bioactivities, such as antibacterial, cytotoxic, and antimalarial activities \[[@b133-marinedrugs-08-01153]\].

5. Bacteriocin-Based Strategy to Select a Probiotic for Aquaculture
===================================================================

In animal or human nutrition, lactic acid bacteria largely dominate the worldwide probiotic market. Actually, they have demonstrated their safety and efficiency over a century. Aquaculture is no exception. Indeed most probiotics used in aquaculture belong to the LAB (for a review the reader is referred to \[[@b140-marinedrugs-08-01153],[@b141-marinedrugs-08-01153]\]). *Bacillus* genus has also been successfully used in aquaculture \[[@b142-marinedrugs-08-01153]\] makes the list longer by adding marine bacteria belonging to *Aeromonas, Pseudomonas, Pseudoalteromonas, Roseobacter* and *Vibrio* and a yeast, *Saccharomyces cerevisiae* \[[@b143-marinedrugs-08-01153]\]. Moreover, the potential of marine actinobacteria as probiotics in aquaculture has been recently reviewed \[[@b144-marinedrugs-08-01153]\]. All the same, marine bacteria are much less developed as a probiotic source in spite of promising results \[[@b143-marinedrugs-08-01153],[@b144-marinedrugs-08-01153]\]. This may be due to a dissuasive legislation.

The use of probiotics in aquaculture is closely controlled by the administration. In the European Union, probiotics are controlled by regulation CE n°1831/2003 (OJ L 268 of 18.10.2003) on the use of additives in animal food. Industrialists have to obtain an authorization from the European Food Safety Authority (EFSA), which controls the beneficial effects of probiotics on animal and human health safety and the environment. The safety assessment of microorganisms is in a guideline issued by a relevant scientific committee (SCAN) in 2001. Several specific tests and studies have to be carried out in order to obtain the QSP (Qualified Presumption of Safety) \[[@b145-marinedrugs-08-01153]\]. In the US, probiotics which are used in animal feed are called "direct fed microbials" and are regulated by the Food and Drug Administration. The efficacy and safety of probiotics are examined by the FDA, which can recognize the microorganism as safe (Generally Recognised As Safe). The GRAS-status can be obtained in two ways: some microorganisms have a long history of safety (find them at <http://www.cfsan.fda.gov/~dms/opa-micro.html>.) or have been recognized by qualified experts as safe under the conditions of intended use \[[@b145-marinedrugs-08-01153]\]. The GRAS concept means that responsibility for safety of the products resides strictly with the producer. To obtain probiotic authorization, the manufacturer has to send a petition to the FDA and the general requirements for this petition are detailed in the US Code of Federal Regulations \[[@b146-marinedrugs-08-01153]\].

We advocate a strategy aiming at preventing establishment of pathogenic bacteria using probiotics. These should be selected from natural indigenous microbial communities associated with marine animals. Bacteriocins are efficient weapons to protect and thus to defend an ecological niche or a nutrient pool. Indeed these peptides combine the most potent activity of related bacteria and a specific spectrum of activity \[[@b45-marinedrugs-08-01153]\]. Thus they constitute a pertinent tool to select a probiotic. So we propose a strategy for probiotic selection based on bacteriocin production ability ([Figure 3](#f3-marinedrugs-08-01153){ref-type="fig"}).

The first step of selection is to screen the animal-associated micro-organisms for antagonistic activities against the selected target cells. This acquisition is one of the major phases of assessment of potential probiotics \[[@b147-marinedrugs-08-01153]\]. Probiotic bacteria for use in aquaculture have to be isolated from indigenous or exogenous microbiota of aquatic vertebrates or invertebrates \[[@b27-marinedrugs-08-01153]\] in order to facilitate establishment and efficiency over temperature and salinity variations of aquaculture farming \[[@b144-marinedrugs-08-01153]\]. This selection is generally carried out by using *in vitro* antagonist tests \[[@b25-marinedrugs-08-01153],[@b144-marinedrugs-08-01153]\]. Then two ways are possible: the use of the inhibitory compounds as an antibiotic or that of bacteria as probiotics ([Figure 3](#f3-marinedrugs-08-01153){ref-type="fig"}). For the former, research has to be carried out in order to determine the nature of inhibitory compounds, the mode of action, and the genetic aspect of BLIS. However, the administration of purified bacteriocins does not appear to be a cost-effective approach. In face of this need, the second alternative seems to be a more feasible approach. When the putative probiotic is selected, the research has to focus on two parts: the evaluation of safety and the beneficial effects under rearing conditions \[[@b147-marinedrugs-08-01153]\]. Safety has to be proved under *in-vivo* and rearing conditions for the host of course, but also for the environment. Then the commercial procedures can be submitted to the authorities concerned.

It is important to note that probiotics producing antagonistic compounds have to be used in a preventive way \[[@b148-marinedrugs-08-01153]\]. Indeed, a review \[[@b149-marinedrugs-08-01153]\] showed that BS107 (a marine bacteria identified as *Roseobacter*) cannot be used for treatment when the pathogen is in sufficient concentration to provoke a disease outbreak. In fact, the authors demonstrate that BS107 (10^6^ cells/mL) doesn't have any probiotic activity when living cells are co -inoculated with *Vibrio pectenicida* A496 (10^4^ cells/mL).

6. Conclusions
==============

Bacteriocins from LAB have demonstrated their remarkable potential as food conservatives \[[@b13-marinedrugs-08-01153],[@b44-marinedrugs-08-01153]--[@b50-marinedrugs-08-01153],[@b63-marinedrugs-08-01153],[@b87-marinedrugs-08-01153],[@b123-marinedrugs-08-01153]\], or as therapeutics for veterinary or medical uses \[[@b13-marinedrugs-08-01153],[@b53-marinedrugs-08-01153]\] or as phytosanitary for plant protection \[[@b51-marinedrugs-08-01153]\]. Extensively studied in LAB and enterobacteriae, little or nothing is known of marine bacteriocins. Only a few have been described, and the fully-characterized ones are exceptions, so knowledge of marine bacteriocins is at the early stage s.

Moreover, the increasing scarcity of marine resources ensures a rise in aquaculture in the next decades but also condemns it to set up effective strategies respectful of the environment. In this context, marine bacteriocins that are produced by LAB or autochthonous associated marine bacteria seem to be a relevant alternative to antibiotics. Based on both bacteriocin diversity described to date and the ocean microbial biodiversity, one can predict the discovery of a true peptide arsenal in the coming years. Such an arsenal will find applications in aquaculture. Indeed, the antibiotic approach has to be redrawn. The approach that we recommend rests on different concepts: (i) the most effective strategy to limit epizooties consists in avoiding contact between host and pathogen; (ii) to eradicate pathogenic bacteria is illusory, it's better to occupy its ecological niche (iii) in the case of infections, it is preferable to use active ingredients with a narrow spectrum of antibacterial activity so as to better target the pathogenic ones and limit the risk of resistance development. Bacteriocins are perfect tools to select as probiotics to apply this strategy. One can dream of protective probiotics made up of several BLIS-producing bacteria acting synergistically against pathogens.

This work is performed within the SeaPro Network ([www.seapro.fr](www.seapro.fr)) in the BIOTECMAR project (contract n°2008-1/032) and is co-financed with the support of the European Union ERDF-Atlantic Area Programme. We acknowledge Hervé Bourdon for English corrections.

*Samples Availability:* Available from the authors.
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###### 

Bacteriocin overview.

  \(A\)                                                                                                                       
  ---------------------------- ----------------- -------------- ------------------- -------------- -------------------------- -------------------------------------------------------------
  **Gracilicutes**                                                                                                            
  *Escherichia coli*           Colicins          Groupe A                           40 to 80       Nuclease/Pore-forming      \[[@b69-marinedrugs-08-01153]\]
                                                 Groupe B                           40 to 80       Nuclease/Pore-forming      \[[@b69-marinedrugs-08-01153]\]
  *Pseudomonas aeruginosa*     Pyocins           R-type         Pyocin R2           270 (AA)       Pore-forming               
                                                 S-type         Pyocin S1,S2,AP41   75/84/94       Phage-tail like            \[[@b70-marinedrugs-08-01153]\]
                                                 F-type         Pyocin F                           Phage-tail like            
  *Hafnia alvei*               Alveicins         Colicin like   Alveicin A, B       408/358 (AA)   Pore forming               \[[@b71-marinedrugs-08-01153]\]
  *Klebsiella pneumonia*       Klebicin          Colicin-like   Klebicin C, D       96             Nuclease                   \[[@b72-marinedrugs-08-01153],[@b73-marinedrugs-08-01153]\]
  *Serratia plymithicum*       Serracin                         Serracin P          66             Phage-tail like            \[[@b74-marinedrugs-08-01153]\]
  *Xanthomonas campestris*     Glynericin                       Glynericin A        50             Phage tail like            \[[@b75-marinedrugs-08-01153],[@b76-marinedrugs-08-01153]\]
  *Yersinia enterocolitica*    Enterocoliticin                                      669            Phage tail like            \[[@b77-marinedrugs-08-01153]\]
  *Erwinia carotovora*         Carotovoricin                    Carotovoricin Er    68/76          Phage tail like            \[[@b78-marinedrugs-08-01153]\]
  **Firmicutes**                                                                                                              
  *Lactobacillus helveticus*   Helveticin J      Class III                          37,5           to be defined              \[[@b79-marinedrugs-08-01153]\]
  *Streptococcus milleri*      Millericin        Class III                          30             Peptidoglycan hydrolysis   \[[@b80-marinedrugs-08-01153]\]
  *Enterococcus faecalis*      Enterolysin       Class III                          34,5           Peptidoglycan hydrolysis   \[[@b81-marinedrugs-08-01153]\]
  *Staphylococcus aureus*      Lysostaphin       Class III                          25             Peptidoglycan hydrolysis   \[[@b82-marinedrugs-08-01153],[@b83-marinedrugs-08-01153]\]

  \(B\)                                                                                                                    
  ---------------------- ----------------- ----------- ----- ----------------- --------- --------- ----------------------- -----------------------------------------------------------------------------------------
  **Gracilicutes**                                                                                                         
  *Escherichia coli*     Microcin          Class I           Microcin B17      3.1       drastic   intracellular enzymes   
                                           Class II    IIa   Microcin V        8.8       light     pore-forming            \[[@b35-marinedrugs-08-01153],[@b59-marinedrugs-08-01153],[@b61-marinedrugs-08-01153]\]
                                                       IIb   Microcin E492     7.9       drastic   pore forming            
  **Firmicutes**                                                                                                           
  Lactic acid bacteria   Class I           A-type      A1    Nisin             3.5       drastic   pore-forming            \[[@b84-marinedrugs-08-01153],[@b85-marinedrugs-08-01153]\]
  (mainly)               or Lantibiotic                A2    Lacticin 481      3         drastic   pore forming            \[[@b86-marinedrugs-08-01153]\]
                                           B-type            Mersacidin        2                                           \[[@b61-marinedrugs-08-01153]\]
                         Class II          class IIa         Pediocin          4.6       light     pore forming            \[[@b48-marinedrugs-08-01153],[@b87-marinedrugs-08-01153]\]
                                           class IIb         Plantaricin E/F   3.5/3.7   light     pore forming            \[[@b88-marinedrugs-08-01153]\]
                                           Class IIc         carnocyclin A     5.8       cyclic    pore forming            \[[@b89-marinedrugs-08-01153],[@b90-marinedrugs-08-01153]\]
                                           Class IId         Lactococcin A     5.8       none      pore forming            \[[@b91-marinedrugs-08-01153]\]
  ***Cyanobacteria***                                                                                                      
  *Prochloron didemni*   microcin --like   \-                Patellamides      0.7       drastic                           \[[@b92-marinedrugs-08-01153]\]

Ref., PTM, AA and ref. respectively mean Review reference, Post-translational modification and amino acids.

###### 

Bacteriocins produced by bacteria isolated from marine environment.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Producing strain                                                                Bacteriocin                   Inhibited strain(s)                                                                 Isolated from                                          MM (kDa)                                                                                                        Ref.
  ------------------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  *Listonella anguillarum* AVP10                                                  Vibriocin AVP10               *Escherichia coli*\                                                                 Healthy and infected catfishes (*Arius thalassimus*)   ?                                                                                                               \[[@b110-marinedrugs-08-01153]\]
                                                                                                                *Listonella anguillarum* AVS9[1](#tfn6-marinedrugs-08-01153){ref-type="table-fn"}                                                                                                                                                                          

  *Vibrio mediterranei*                                                           BLIS                          *V. parahaemolyticus*\                                                              Fresh & frozen seafood                                 63--65[a](#tfn2-marinedrugs-08-01153){ref-type="table-fn"}                                                      \[[@b111-marinedrugs-08-01153]\]
                                                                                                                *V. mediterranei* 5                                                                                                                                                                                                                                        

  *Vibrio harveyi* VIB 571                                                        BLIS                          *Vibrio harveyi*[1](#tfn6-marinedrugs-08-01153){ref-type="table-fn"}\               \-                                                     \~32[a](#tfn2-marinedrugs-08-01153){ref-type="table-fn"},[b](#tfn3-marinedrugs-08-01153){ref-type="table-fn"}   \[[@b112-marinedrugs-08-01153]\]
                                                                                                                *V. fischeri*\                                                                                                                                                                                                                                             
                                                                                                                *V. gazogenes*\                                                                                                                                                                                                                                            
                                                                                                                *V. parahaemolyticus*                                                                                                                                                                                                                                      

  *Vibrio harveyi (Beneckea harveyi* SY)                                          Harveyicin SY                 *V. harveyi*[1](#tfn6-marinedrugs-08-01153){ref-type="table-fn"}                    area of Galveston Island                               24                                                                                                              \[[@b114-marinedrugs-08-01153],[@b115-marinedrugs-08-01153]\]

  *Vibrio vulnificus*                                                             IW1                           *V. vulnificus*\                                                                    Water samples from Wilmington (NC, USA)                9                                                                                                               \[[@b116-marinedrugs-08-01153]\]
                                                                                                                *V. cholera*                                                                                                                                                                                                                                               

  BC1                                                                             *V. parahaemolyticus*         7,5                                                                                                                                                                                                                                                        

  BC2                                                                             *Vibrio* spp.\                1,35                                                                                                                                                                                                                                                       
                                                                                  *Plesiomonas shigelloides*\                                                                                                                                                                                                                                                              
                                                                                  *E. coli*                                                                                                                                                                                                                                                                                

  *Vibrio* sp. Strain NM 10                                                       BLIS                          *Pasteurella piscicida* K-III;\                                                     *Leiognathus nuchalis* intestine                       \< 5[d](#tfn5-marinedrugs-08-01153){ref-type="table-fn"}                                                        \[[@b117-marinedrugs-08-01153]\]
                                                                                                                *E. coli*;\                                                                                                                                                                                                                                                
                                                                                                                *V. vulnificus*\                                                                                                                                                                                                                                           
                                                                                                                *Enterococcus seriolicida*                                                                                                                                                                                                                                 

  Bacteriocinogenic strain marine strain ZM81 (Gram positif pleomorphic strain)   Bacteriocins/BLIS             Marine bacterial strain ZM19                                                        Open sea region of Karachi coast                       \>10                                                                                                            \[[@b120-marinedrugs-08-01153]\]

  *Aeromonas hydrophila*                                                          BLIS                          *Staphylococcus aureus* strains                                                     Water tank containing alligators                       ?                                                                                                               \[[@b118-marinedrugs-08-01153]\]\
                                                                                                                                                                                                                                                                                                                                                                           \[[@b119-marinedrugs-08-01153]\]

  *Pseudoalteromonas* Species Strain X153                                         Antibiotic protein P-153      Ichthyopathogenic *Vibrio*[1](#tfn6-marinedrugs-08-01153){ref-type="table-fn"}\     Substrates on the littoral of Brittany                 280[a](#tfn2-marinedrugs-08-01153){ref-type="table-fn"},[b](#tfn3-marinedrugs-08-01153){ref-type="table-fn"}    \[[@b121-marinedrugs-08-01153]\]
                                                                                                                *Staphylococcus epidermidis*\                                                                                                                                                                                                                              
                                                                                                                *Propionibacterium acnes*\                                                                                                                                                                                                                                 
                                                                                                                *Propionibacterium granulosum*                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Molecular mass was evaluated using sodium dodecyl sulfate polyacrylamide gel electrophoresis;

size-exclusion chromatography,

Mass Spectrometry or

ultrafiltration.

aquacole pathogen.

bacteriocin isolated from fish intestine.

Unknown molecular mass.

###### 

Bacteriocin produced by Lactic Acid Bacteria isolated from marine animal.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Producing strain                                    Bacteriocin       Inhibited strain(s)                  Isolated from                                                  MM (kDa)   Ref.
  --------------------------------------------------- ----------------- ------------------------------------ -------------------------------------------------------------- ---------- ----------------------------------------------------------------
  *Enterococcus faecium* LHICA 28.4, 34.5, 40.4, 46   Enterocin P       *Carnobacterium maltaromaticum*\     Turbot muscle                                                             \[[@b124-marinedrugs-08-01153]\]
                                                                        *Listeria monocytogenes*\                                                                                      
                                                                        *Staphylococcus aureus*                                                                                        

  *Enterococcus faecium* ALP7                         bac ALP7          *Listeria monocytogenes*             Non-fermented shellfish including oysters, mussels and clams   \<10       \[[@b125-marinedrugs-08-01153]\]

  *Pediococcus pentosaceus* ALP57                     bac ALP57         *Bacillus subtilis*\                                                                                           
                                                                        *Enterococcus faecalis*\                                                                                       
                                                                        *Lactobacillus brevis gravensis;*\                                                                             
                                                                        *Lactobacillus curvatus*\                                                                                      
                                                                        *Listeria innocua*                                                                                             

  *Carnobacterium divergens* V41                      Divercin V41      *Listeria monocytogenes*             Salmon intestine                                               4,509      \[[@b126-marinedrugs-08-01153]--[@b129-marinedrugs-08-01153]\]

  *Carnobacterium piscicola* V1                       Piscicocin V1a\   *Listeria monocytogenes*             Trout intestine                                                4,416\     \[[@b128-marinedrugs-08-01153],[@b130-marinedrugs-08-01153]\]
                                                      Piscicocin V1b                                                                                                        4,526      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
